Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 1/2011

01-02-2011

Idiosyncratic Drug-Induced Liver Injury: A Clinical Update

Authors: Haripriya Maddur, Naga Chalasani

Published in: Current Gastroenterology Reports | Issue 1/2011

Login to get access

Abstract

Drug-induced liver injury (DILI) is a rare but potentially devastating adverse drug reaction. Its presentation can range from asymptomatic elevation in liver biochemistries to fulminant liver failure. Over the past decade, clinical and research interest in the field of idiosyncratic DILI has been intense, and several new findings have been reported. In this article, we provide an update on implicated agents, clinical features, outcomes, and the results of recently reported genetic studies.
Literature
1.
Larson AM, Polson J, Fontana RJ, et al.: Acetaminophen-induced acute liver failure: results of a United States multi-center, prospective study. Hepatology 2005, 42:1364–1372.CrossRefPubMed
2.
Larrey D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002, 22:145–155.CrossRefPubMed
3.
• Chalasani N, Fontana RJ, Herbert L, et al.: Causes, clinical features, and outcomes from a prospective study of drug-Induced liver injury in the United States. Gastroenterology 2008, 135:1924–1934. This paper reports preliminary findings of an ongoing study (nearly 800 patients enrolled) conducted in the United States. This study confirmed that DILI with jaundice carries high mortality. A surprising finding of this study is that about 0.5% of enrolled patients had unsuspected acute hepatitis C masquerading as DILI. CrossRefPubMed
4.
Andrade RJ, Lucena I, Fernandez C, et al: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512–521.PubMed
5.
Ibanez L, Perez E, Vidal X, Laporte JR: Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002, 37:592–600.CrossRefPubMed
6.
Alla V, Abraham J, Siddique J, et al.: Autoimmune liver disease triggered by statins: report of 3 instances and review of literature. J Clin Gastroenterol 2006, 40:757–761.CrossRefPubMed
7.
Lim JR, Fraught PR, Chalasani N, Molleston J: Severe liver injury after starting atomoxetine (Strattera) in two children. J Pediatrics 2006, 148:831–834.CrossRef
8.
Bjornsson E, Talwalkar J, Treeprasertsuk S, et al.: Drug induced Autoimmune Hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040–2048.PubMed
9.
• Chalasani N, Bjornsson E: Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138:2246–2259. This recently published review article summarizes nongenetic and genetic risk factors for developing idiosyncratic DILI. CrossRefPubMed
10.
Chalasani N: Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005, 41:690–695.CrossRefPubMed
11.
Cohen D, Anania F, Chalasani N: Report of the liver expert panel. Statin Safety Task Force, National Lipid Association. Am J Cardiol 2006, 97(Suppl):77C–81C.CrossRefPubMed
12.
Chalasani N, Aljadhey H, Kesterson J, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287–1292.CrossRefPubMed
13.
Vuppalanchi R, Teal E, Chalasani N: Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62–65.CrossRefPubMed
14.
Targher G, Day CP, Bonor E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341–1350.CrossRefPubMed
15.
Browning JD: Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006, 44:466–471.CrossRefPubMed
16.
Nunez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010, 52:1143–1155.CrossRefPubMed
17.
Park WB, Kim W, Lee KL, et al.: Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 2010, 61:323–329.CrossRefPubMed
18.
Uetrecht J: Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007, 47:513–539.CrossRefPubMed
19.
• Lammert C, Einarsson S, Saha C, et al.: Relationship between daily dose of oral medications and idiosyncratic drug induced liver injury (DILI): search for signals. Hepatology 2008, 47:2003–2009. This study showed that oral compounds administered at doses ≥50 mg/day are at higher risk to cause hepatotoxicity than those given at lower doses. This study consisted of several datasets that exhibited a similar pattern of dose-dependency. CrossRefPubMed
20.
Lammert C, Niklasson A, Bjornsson E, Chalasani N: Oral medications with significant hepatic metabolism are at higher risk for hepatic adverse events. Hepatology 2010, 51:615–620.PubMed
21.
Andrade JR, Lucena MI, Kaplowitz N, et al.: Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44:1581–1588.CrossRefPubMed
22.
Fontana RJ, Watkins PB, Bonkovsky HL, et al.: Rationale, design and conduct of the drug induced liver injury network prospective study. Drug Safety 2009, 32:55–68.CrossRefPubMed
23.
Björnsson E, Kalaitzakis E, Olsson R: The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007, 25:1411–1421.CrossRefPubMed
24.
Benichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11:272–276.CrossRefPubMed
25.
Benichou C, Danan G, Falhault A, et al.: Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 45:1331–1336.CrossRef
26.
Rockey DC, Seeff LB, Rochon J, et al. for the Drug-Induced Liver Injury Network: A structured assessment process to assign causality in drug induced liver injury. Hepatology 2010, 51:2117–2126.PubMed
27.
Papay JI, Clines D, Rafi R, et al.: Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009, 54: 84–90.CrossRefPubMed
28.
Dalton HR, Fellows HJ, Stableforth W, et al.: The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007, 26:1429–1435.CrossRefPubMed
29.
30.
•• Kindmark A, Jawaid A, Harbron CG, et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008, 8:186–195. This article describes the first genome-wide association study conducted to explore the genetic basis of DILI in humans. Ximelagatran, a compound with great promise, was abandoned because of idiosyncratic DILI. This study showed a strong relationship between HLA DRB1*07 and HLA DQA1*02 and liver injury from ximelagatran. CrossRefPubMed
31.
•• Daly AK, Donaldson PT, Bhatnagar P, et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816–821. A landmark article published by the International SAE consortium showed an exceptionally strong relationship between HLA B*5701 and flucloxacillin hepatotoxicity. This compound is not available in the United States. CrossRefPubMed
32.
33.
34.
Bjornsson E: Drug induced liver injury: Hy’s rule revisited. Clin Pharmacol Ther 2006, 79:521–528.CrossRefPubMed
35.
Lewis JH: Hy’s law, the “rezulin rule,” and other predictors of severe drug-induced hepatotoxicity; putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006, 15:221–229.CrossRefPubMed
36.
Lee WM, Hynan LS, Rossaro L, et al.: Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856–864.CrossRefPubMed
Metadata
Title
Idiosyncratic Drug-Induced Liver Injury: A Clinical Update
Authors
Haripriya Maddur
Naga Chalasani
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 1/2011
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0154-8

Other articles of this Issue 1/2011

Current Gastroenterology Reports 1/2011 Go to the issue

ReviewPaper

Pulmonary Complications of Cirrhosis

ReviewPaper

The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection

Erratum

Erratum to: Novel Approaches to Inhibition of Gastric Acid Secretion

ReviewPaper

Advances in Alcoholic Liver Disease

CLINICAL TRIAL REPORT

Clinical Trial Report: Treatment of Nonalcoholic Steatohepatitis with Vitamin E

ReviewPaper

Prevention and Treatment of Postoperative Crohn’s Disease Recurrence: An Update for a New Decade
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits